31 August 2020 - Document open to public comment until 21 September 2020. ...
21 July 2020 - Given the FDA’s recent decision to not grant accelerated approval for the treatment, ICER has canceled its ...
19 March 2020 - Public comment period on preliminary draft now open until 24 June 2020; requests to make oral comment ...
12 March 2020 - Three new treatments use different mechanisms to improve patient outcomes, offering important options for patients. ...
25 February 2020 - Evidence on new agents lasmiditan, ubrogepant, and rimegepant judged inadequate to demonstrate superiority over more affordable triptans. ...
20 February 2020 - Public comment period now open until 18 March 2020; requests to make oral comment during public meeting ...
23 January 2020 - ICER’s ongoing assessment emphasises that policy makers will need to consider, in addition to traditional measures ...
10 January 2020 - Lasmiditan, rimegepant, and ubrogepant all perform better than placebo, but evidence is not adequate to distinguish among ...
9 January 2020 - Despite upadacitinib reaching common thresholds for cost-effectiveness when compared to adalimumab, the independent appraisal committee’s votes on ...
9 December 2019 - Oral GLP-1 semaglutide achieves commonly cited thresholds for cost-effectiveness but is less cost-effective than SGLT-2 competitor empagliflozin. ...
26 November 2019 - Using adalimumab as the comparator, upadacitinib’s value-based price benchmark is between $44,000-$45,000 per year; at December 9 ...
12 November 2019 - Collaborative project with NICE and CADTH leads to important adaptations for ICER’s methods including creation of optimistic ...
11 October 2019 - Public comment period extended through 8 November 2019; public meeting now to take place on 9 December ...
26 September 2019 - Public comment period now open until 24 October 2019; requests to make oral comment during public ...
12 September 2019 - Pricing of rivaroxaban and icosapent ethyl aligns well with treatments’ benefits for patients; expert roundtable will discuss ...